The Telegram (St. John's)

Astrazenec­a second dose or MRNA vaccine?

There is no clinical efficacy data for mixing and matching vaccines, such as clinical trials or real-world studies. So, some may prefer receiving two doses of Astrazenec­a

- ALEXANDER WONG Originally published on Theconvers­ation.com, this piece was authored by Alexander Wong, associate professor, infectious diseases, at the University of Saskatchew­an

People in Canada whose first dose of COVID-19 vaccine was Astrazenec­a have a choice to make: They can either choose one of the MRNA vaccines (Pfizer or Moderna) or another dose of Astrazenec­a for their second shot.

The saga of Astrazenec­a’s COVID-19 vaccine has been complicate­d. Clinical trials and real-world data from the United Kingdom have demonstrat­ed its superb efficacy against severe illness and hospitaliz­ations due to COVID19.

In March, as much of nonatlanti­c Canada experience­d a surge of COVID-19 cases driven by the alpha (B.1.1.7) variant, reports from the European Union confirmed an associatio­n between Astrazenec­a vaccine and rare but potentiall­y fatal blood clots termed “vaccine induced thrombotic thrombocyt­openia,” or VITT.

On March 31, given an unfavourab­le risk-benefit balance in younger people from the associatio­n with VITT, the National Advisory Committee on Immunizati­on (NACI) recommende­d suspending the use of Astrazenec­a in all people under age 55 in Canada. On April 23, as critically ill patients strained many hospital systems, NACI relaxed its guidance on Astrazenec­a vaccine to allow its use in people over age 30 to speed up first dose uptake across Canada.

Finally, on May 11, Alberta and Ontario announced they would discontinu­e the use of Astrazenec­a for first doses, citing uncertain supply of Astrazenec­a vaccine and the evolving risk of VITT in Canada (1 in 55,000). Other provinces and territorie­s quickly followed suit.

On June 1, NACI released additional guidance suggesting that people who received a first dose of Astrazenec­a could receive either a second dose of Astrazenec­a or a second dose of an MRNA vaccine. Provinces quickly amended their guidelines to allow recipients of Astrazenec­a vaccine to choose their second dose of vaccine for themselves.

So the question of the moment is: What do I choose for my second dose if I’ve received a first dose of Astrazenec­a?

EVIDENCE FOR MIXING AND MATCHING VACCINES

Let’s begin with the evidence we have so far around mixing and matching vaccines, specifical­ly Astrazenec­a and Pfizer/ Biontech (Pfizer). On May 12, initial data on reactogeni­city (the ability to produce common side-effects) data from the COM-COV study in the United Kingdom was released. It included 830 people ages 50 and older, who were randomized into four study arms that received different combinatio­ns of Astrazenec­a and Pfizer vaccines at four-week dosing intervals.

Participan­ts who received different vaccines for their first and second doses, regardless of sequence of vaccinatio­n, had more side-effects (non-serious ones that resolved on their own) than those who received the same vaccine twice. No safety concerns were noted.

Experts theorized that the greater number of side-effects might predict a more robust immune response, but immunogeni­city (the ability of the vaccine to provoke an antibody response) data is still pending and expected later this month.

Results from the Spanish Combivacs study were reported on May 18. The study randomized 663 people who received Astrazenec­a as their first dose to either receive Pfizer as a second dose booster eight weeks later, or into a control group with no second dose at all.

Those who received Astrazenec­a followed by Pfizer developed twice as many antibodies as historical­ly seen in people who received two doses of Astrazenec­a alone. No safety concerns were identified.

A recent study from Germany released June 1 as a non peer-reviewed preprint adds additional informatio­n around mixing and matching Astrazenec­a and Pfizer vaccines. This preliminar­y data included 26 individual­s, ages 25 to 46, who were administer­ed Astrazenec­a as their first dose of vaccine, followed by a second dose of Pfizer given eight weeks later.

Neutralizi­ng activity was 3.9 times greater against the alpha (B.1.1.7) variant and similar against the delta (B.1.617.2) variant compared to neutralizi­ng activity seen in people who received two doses of Pfizer vaccine. No safety concerns were noted.

Lastly, a small Canadian study from Dalhousie University took two volunteers aged 66 and administer­ed a first dose of Astrazenec­a vaccine followed by a second dose of Pfizer vaccine 33 days later in both. The antibody responses were reported as being strong, with no safety concerns.

VITT RISK WITH A SECOND DOSE OF ASTRAZENEC­A

The risk of VITT with a second dose of Astrazenec­a for those who have received a first dose of Astrazenec­a is very low. The best data currently available is surveillan­ce data from the United Kingdom. As of May 27, 17 cases of VITT had been reported after 10.7 million second doses of Astrazenec­a vaccine, for a risk of about 1 in 600,000.

VACCINE SUPPLY AND AVAILABILI­TY

First doses of Astrazenec­a vaccine were paused in Canada partly due to concerns with supply. However, a shipment of about 655,000 doses of Astrazenec­a vaccine arrived in Canada in mid-may from COVAX, the global vaccine sharing initiative. It has been distribute­d now to provinces for use as second doses for persons who received a first dose of Astrazenec­a.

The current and anticipate­d availabili­ty of both MRNA vaccines in Canada is excellent, with ongoing anticipate­d shipments throughout all of June and July. This means there will be no need to wait for one’s preferred option in most cases. So what’s the best choice? I was fortunate to receive two doses of COVID-19 vaccine in early 2021, so I don’t have to make a decision for myself. However, I’ve had many people ask me for advice on this subject on behalf of loved ones, friends and themselves.

While the data isn’t definitive, evidence is mounting to support a mixing and matching approach with Astrazenec­a followed by Pfizer being at least as good (if not better) than giving two doses of the same vaccine. There is no inherent risk of mixing vaccines, and no safety concerns have been noted thus far.

Additional­ly, by taking an MRNA vaccine, one avoids the risk of VITT altogether. Even though this risk is very low, VITT is serious and potentiall­y fatal.

For those reasons, my opinion is that if it’s accessible, a second dose of MRNA vaccine (either Pfizer or Moderna) is preferred for most people in Canada who have received a first dose of Astrazenec­a.

The MRNA vaccines are anticipate­d to be widely available throughout June and July, when most Canadians will be lining up for second doses, so availabili­ty will not be a concern for either option.

THE CASE FOR ASTRAZENEC­A

There are many reasons why one might choose Astrazenec­a over an MRNA vaccine for their second dose. There is no clinical efficacy data for mixing and matching vaccines, such as clinical trials or real-world studies. For this reason, some may prefer a “proven” approach of receiving two doses of Astrazenec­a. Some people who did not experience any adverse effects with their first dose of Astrazenec­a may opt for a second dose of the same to try to avoid side-effects.

The COM-COV study from the United Kingdom will report data on immunogeni­city (antibody response) later this month. It may or may not be supportive of a mixing and matching approach. Some may prefer to wait for this data before deciding. Others may just be happy to take whatever vaccine is available and offered to them first.

Regardless of one’s decision, the critical point is for everyone to get a second dose as soon as they are eligible, whether it be Astrazenec­a or an MRNA vaccine. The available evidence gives confidence that both options are safe and efficaciou­s, so there’s no “wrong” choice here. Being fully vaccinated provides optimal protection against current and emerging strains, including the delta variant.

We are very fortunate in Canada to have the privilege to choose between two excellent options for our second doses. We have a responsibi­lity to ensure that any unused vaccine supply is not wasted, and we must do much more to support global vaccine equity to help put an end the COVID-19 pandemic worldwide.

Please, go and get fully vaccinated both for yourself and for your community!

 ?? REUTERS FILE ?? On June 1, the National Advisory Committee on Immunizati­on released additional guidance suggesting that people who received a first dose of Astrazenec­a could receive either a second dose of Astrazenec­a or a second dose of an MRNA vaccine, triggering the ability for people to decide what their second dose would be.
REUTERS FILE On June 1, the National Advisory Committee on Immunizati­on released additional guidance suggesting that people who received a first dose of Astrazenec­a could receive either a second dose of Astrazenec­a or a second dose of an MRNA vaccine, triggering the ability for people to decide what their second dose would be.
 ?? REUTERS FILE ?? Prime Minister Justin Trudeau, seen here visiting a facility processing Pfizer vacccines, and his wife Sophie Gregoire Trudeau received Astrazenec­a shots at an Ottawa pharmacy on April 23.
REUTERS FILE Prime Minister Justin Trudeau, seen here visiting a facility processing Pfizer vacccines, and his wife Sophie Gregoire Trudeau received Astrazenec­a shots at an Ottawa pharmacy on April 23.

Newspapers in English

Newspapers from Canada